explore -WSS

explore

author：leisure time 2025-08-11 09:49:45 - browse：17

illustration of one blue dna strand — Adobe

The Food and Drug Administration is convening a meeting of outside experts on Tuesday to review exa-cel, a CRISPR-based treatment for sickle cell disease made by Vertex Pharmaceuticals and CRISPR Therapeutics.

Tuesday’s meeting is set up a bit differently than most FDA advisory panels. The agency has not raised any concerns about exa-cel’s efficacy or safety, and there will not be a typical vote at the end of the day on whether the data from exa-cel’s pivotal clinical trial support an approval as a treatment for sickle cell disease.

Instead, the FDA is seeking input about the methods used by Vertex and CRISPR Therapeutics to evaluate the risk of inadvertently making unwanted changes to patients’ DNA — so-called off-target editing — when exa-cel is administered.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Device maker Teleflex to acquire urology company for $600M

leisure time

WSS

Sudafed saga points to U.S. issues with evaluating older drugs

Menendez indictment could see pharma lose a key ally

Medicaid, Medicare dual

STAT Virtual Event: How to Increase Diversity in Clinical Trials

Senator probes 340B programs at Cleveland Clinic, Bon Secours

What causes rare myocarditis in young men after Covid vaccines?

leisure time

explore

leisure time

Virginia high school admissions case could be legal follow

The haunting brain science of long Covid

Medicare proposal to cover medical devices draws a mixed reaction

Biogen shutters digital health group, ends Apple study, in cost cutting move

In Memoriam: Notable people who died in 2023

'Investigate these claims': UFO transparency at center of House hearing

Affirmative action in medical school literally saved lives

Why patients can’t get everything they want on drug pricing

How one medical school became remarkably diverse

Rise in cancer among younger people worries and puzzles doctors

leisure time

New Alzheimer's drugs heat up race for early detection blood tests

Roche’s Alnylam deal shows drug firms interested in heart drugs

Paxlovid should be available without a positive Covid test

Covid vaccines: Private market messier than government rollout

Russian fighter jet damages US Reaper drone with flare over Syria: Officials

Medicare drug price negotiation program allowed for now

leisure time

leisure time

Wikipedia

entertainment